EcoDrugPlus

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSDARG00000057741
Gene Symbol: NR1H4
21 Enzyme and pathways 5 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSDARG00000025032
Gene Symbol: NR3C1
12 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSDARG00000102082
Gene Symbol: NR3C2
12 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSDARG00000010756
Gene Symbol: NOD2
33 Enzyme and pathways 5 Cross references
167 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSDARG00000071209
Gene Symbol: OPRL1
7 Enzyme and pathways 5 Cross references
191 Possible Orthologues:

Opioid Receptor, Delta 1a

Ensembl ID : ENSDARG00000041660
Gene Symbol: OPRD1A
7 Enzyme and pathways 5 Cross references
128 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSDARG00000037159
Gene Symbol: OPRD1B
5 Cross references
240 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSDARG00000006894
Gene Symbol: OPRK1
7 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSDARG00000039434
Gene Symbol: OPRM1
9 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSDARG00000033956
Gene Symbol: OXTR
8 Enzyme and pathways 5 Cross references
193 Possible Orthologues:

Oxytocin Receptor Like

Ensembl ID : ENSDARG00000044175
Gene Symbol: OXTRL
5 Cross references
136 Possible Orthologues:

P21 Protein (Cdc42/rac)-Activated Kinase 4

Ensembl ID : ENSDARG00000018110
Gene Symbol: PAK4
5 Cross references
163 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).